Persisting corneal erosion under cetuximab (Erbitux) treatment (Epidermal growth factor receptor antibody)
Persisting corneal erosion under cetuximab (Erbitux) treatment (Epidermal growth factor receptor antibody)
复制标题
DOI：
10.1097/ico.0b013e318166f483
复制
发表时间：
2008-06-01
期刊：
影响因子：
2.8
通讯作者：
Kruse, Friedrich E.
中科院分区：
文献类型：
--
作者：
Foerster, Claudia G.;Cursiefen, Claus;Kruse, Friedrich E.
目的：报道抗表皮生长因子受体的单抗西妥昔单抗(Erbitux)治疗后持续的角膜侵蚀和毛发增大的眼部副作用。方法：62岁的结直肠癌患者接受了包括西妥昔单抗的联合化疗，表现为睫毛生长加速，双侧持续的角膜侵蚀对保守治疗耐药。结果：局部应用EGF后，角膜上皮损伤迅速改善，术后7天(左眼)和19天(右眼)上皮细胞完全愈合，同时继续应用西妥昔单抗。结论：西妥昔单抗(Erbitux)可导致角膜创面愈合障碍，为眼部副反应。相关患者可能受益于EGF眼药水的应用。
Purpose: To report persisting corneal erosion and trichomegaly as ocular side effects of cetuximab (Erbitux) treatment, a monoclonal antibody against the epidermal growth factor (EGF) receptor.Methods: A 62-year-old patient was treated with combined chemotherapy including cetuximab for colorectal carcinoma and showed accelerated growth of eyelashes with persistent bilateral corneal erosions resistant to conservative treatment. Topical EGF was successfully applied as an experimental treatment to antagonize the inhibitory effect of the EGF receptor antibody.Results: Topical application of EGF led to rapid improvement, with complete healing of the epithelial defect after 7 (left eye) and 19 days (right eye) while application of cetuximab was continued.Conclusions: Cetuximab (Erbitux) can cause impairment of corneal wound healing as an ocular side effect. Patients concerned may benefit from application of EGF eyedrops.